Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesLabcorp Holdings Inc.

Labcorp Holdings Inc.

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
372.58 USD 6.01 ( 1.64%)
Last update at 2026-11-09T17:49:00Z
VOLUME
210600
Market Cap
19019.30M
P/E
23.09

Momentum Score

…

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications to enable patients to check test results; and online applications for MCOs and accountable care organizations; and end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves MCOs, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
364.79
Low
372.58
High
52 Week Price Range
178.37
Low
225.27
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Laboratory Corporation of America Holdings operates a large clinical laboratory and drug-development services business, providing diagnostic testing, clinical trial support and related information services. Long-term growth may be driven by aging populations, rising demand for genomic and specialty testing, precision medicine and outsourced clinical trials, and the company may appear positioned to benefit from scale and diversified recurring revenue.
Principal risks include reimbursement and margin pressure from payors and regulators, regulatory and compliance exposure, competition from other labs and in‑house testing, and sensitivity to pharmaceutical R&D cyclicality.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
366.57
Dividend Yield
1.29%
Revenue TTM
15070.90M
Revenue Per Share
171.07
Gross Profit TTM
4385.10M
Debt / Equity
0.62
ROE
9.57%
Net Debt
5864.90M
ROCE
10.39%
Diluted EPS TTM
9.70

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 1582.60M 3126.60M 2219.10M 1104.90M 1268.30M
Minority interest -1.50M -2.20M 20.70M 20.10M 0.20M
Net income 1279.10M 2377.30M 1556.10M 823.80M 883.70M
Selling general administrative 1996.60M 1952.10M 1729.00M 1624.50M 1570.90M
Gross profit 4385.10M 5624.30M 4952.80M 3252.50M 3176.40M
Reconciled depreciation 633.90M 745.10M 624.70M 577.20M 552.10M
Ebit 1773.90M 3259.50M 2445.40M 1330.20M 1553.10M
Ebitda 2743.20M 4116.70M 3543.60M 1968.60M 2105.20M
Depreciation and amortization 969.30M 857.20M 1098.20M 638.40M 552.10M
Non operating income net other - 79.20M - - 186.80M
Operating income 1773.90M 3259.50M 2445.40M 1330.20M 1325.70M
Other operating expenses 12747.60M 12818.30M 11030.40M 10170.00M 9959.60M
Interest expense 180.30M 212.10M 207.40M 240.70M 244.20M
Tax provision 302.00M 747.10M 662.10M 280.00M 384.40M
Interest income 166.00M 175.40M 194.20M 212.30M 225.10M
Net interest income -180.30M -212.10M -207.40M -240.70M -244.20M
Extraordinary items - - - - -44.90M
Non recurring - 43.10M - - 48.10M
Income tax expense 302.00M 747.10M 662.10M 280.00M 384.40M
Total revenue 14876.80M 16120.90M 13978.50M 11554.80M 11333.40M
Total operating expenses 2255.90M 2321.70M 2004.70M 1867.70M 1802.60M
Cost of revenue 10491.70M 10496.60M 9025.70M 8302.30M 8157.00M
Total other income expense net -191.30M -132.90M -226.30M -225.30M 138.70M
Net income from continuing ops 1280.60M 2379.50M -0.90M 824.90M 883.90M
Net income applicable to common shares 1279.10M 2377.30M -0.90M 823.80M 883.70M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 20155.10M 20385.40M 20071.70M 18021.40M 16185.30M
Intangible assets 3946.90M 3735.50M 3961.10M 4034.50M 3911.10M
Other current assets 707.00M 478.10M 364.80M 373.70M 309.00M
Total liab 10058.50M 10112.50M 10712.00M 10454.40M 9213.90M
Total stockholder equity 10096.60M 10272.90M 9359.70M 7567.00M 6971.40M
Deferred long term liab - 762.90M - - 940.00M
Other current liab 1068.80M 1404.10M 1357.70M 942.40M 870.00M
Common stock 8.10M 8.50M 9.00M 9.00M 11.70M
Capital stock 8.10M 8.50M 9.00M 9.00M 11.70M
Retained earnings 10581.70M 10456.40M 9402.30M 7903.60M 7079.80M
Other liab 1079.30M 1165.40M 1431.80M 1326.00M 1274.00M
Good will 8121.00M 7958.90M 7751.50M 7865.00M 7360.30M
Other assets 440.30M 484.20M 350.90M 356.50M 277.70M
Cash 430.00M 1472.70M 1320.80M 337.50M 426.80M
Cash and equivalents 430.00M 1472.70M 1320.80M 337.50M 426.80M
Total current liabilities 3078.50M 2782.90M 3078.50M 2646.80M 1878.90M
Current deferred revenue 582.10M 558.50M 506.50M 451.00M 356.40M
Net debt 5864.90M 4869.90M 5435.60M 6745.10M 5633.00M
Short term debt 492.80M 199.00M 575.40M 621.10M 17.90M
Short long term debt 301.30M 1.50M 376.70M 415.20M 10.00M
Short long term debt total 6294.90M 6342.60M 6756.40M 7082.60M 6059.80M
Other stockholder equity -493.20M -192.00M 110.30M 26.80M 343.00M
Property plant equipment 2956.20M 2815.40M 2809.30M 2724.30M 1784.70M
Total current assets 4625.00M 5330.50M 5125.40M 2981.20M 2835.40M
Long term investments 65.70M 60.90M 73.50M 84.90M 60.50M
Net tangible assets -1971.30M -1421.50M -2352.90M -4332.50M -4300.00M
Short term investments - - 73.00M 9.10M -
Net receivables 3017.40M 2978.30M 3016.60M 2025.30M 1862.30M
Long term debt 5038.80M 5416.50M 5419.00M 5789.80M 6041.90M
Inventory 470.60M 401.40M 423.20M 244.70M 237.30M
Accounts payable 934.80M 621.30M 638.90M 632.30M 634.60M
Noncontrolling interest in consolidated entity - 20.60M - - 19.10M
Accumulated other comprehensive income -493.20M -192.00M -161.90M -372.40M -463.10M
Common stock total equity - 8.50M 9.00M 9.00M 11.70M
Retained earnings total equity - 10456.80M - - 7079.80M
Treasury stock - - - - -1108.10M
Non currrent assets other 432.70M 462.60M 410.00M 435.40M 231.60M
Non current assets total 15530.10M 15054.90M 14946.30M 15040.20M 13349.90M
Capital lease obligations 954.80M 924.60M 960.70M 902.60M 58.90M
Long term debt total 5122.40M 5501.10M 5503.40M 5880.90M 6041.90M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1652.20M -14.60M -643.20M -1283.10M -4.00M
Change to liabilities 342.40M 34.80M 43.10M 25.30M 37.30M
Total cashflows from investing activities -1652.20M -884.60M -643.20M -1283.10M 206.70M
Net borrowings - -375.00M -412.20M 210.10M -409.30M
Total cash from financing activities -1322.20M -2065.80M -517.40M -252.70M -1389.90M
Change to operating activities -816.20M -344.10M 252.50M -174.70M -30.10M
Net income 1280.60M 2379.50M 1557.00M 824.90M 883.90M
Change in cash -1042.70M 151.90M 983.30M -89.30M 110.20M
Begin period cash flow 1472.70M 1320.80M 337.50M 426.80M 316.60M
End period cash flow 430.00M 1472.70M 1320.80M 337.50M 426.80M
Total cash from operating activities 1955.90M 3109.60M 2135.30M 1444.70M 1305.40M
Issuance of capital stock 50.60M 51.70M 55.90M 64.70M 69.10M
Depreciation 633.90M 745.10M 624.70M 577.20M 552.10M
Other cashflows from investing activities -1170.30M -424.20M 3.10M 1.70M 590.50M
Dividends paid -195.20M -1000.00M -151.70M -2395.00M 467.20M
Change to inventory -45.50M 2.80M -196.60M -21.90M -18.90M
Change to account receivables 15.90M 222.00M -913.40M -64.10M 50.20M
Sale purchase of stock -1100.00M -1668.50M -100.00M -450.00M -700.00M
Other cashflows from financing activities 709.80M 1926.00M 242.30M 4712.50M 880.00M
Change to netincome 646.30M 56.00M 611.10M 144.00M -60.50M
Capital expenditures 481.90M 460.40M 381.70M 400.20M 379.80M
Change receivables - - - - -30.80M
Cash flows other operating - - - - -57.70M
Exchange rate changes - - - - -12.00M
Cash and cash equivalents changes - - - - 110.20M
Change in working capital -603.40M -263.70M -856.90M -294.40M -70.30M
Stock based compensation 144.10M 153.70M 111.70M 107.00M 91.60M
Other non cash items 482.40M 170.90M 745.80M 200.80M -174.10M
Free cash flow 1474.00M 2649.20M 1753.60M 1044.50M 925.60M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
LH
Labcorp Holdings Inc.		 6.01
1.64%		 372.58 23.09 15.17 1.25 2.37 1.61 12.59
TMO
Thermo Fisher Scientific Inc		 12.74
1.83%		 707.50 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 3.52
1.53%		 233.77 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -0.93
3.65%		 24.52 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 1.01
4.03%		 26.02 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

Labcorp Holdings Inc.

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications to enable patients to check test results; and online applications for MCOs and accountable care organizations; and end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves MCOs, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

358 South Main Street, Burlington, NC, United States, 27215

336 229 1127

https://www.labcorp.com

60000

Name Title Year Born
Mr. Adam H. Schechter Pres, CEO & Chairman 1965
Mr. Glenn A. Eisenberg CFO & Exec. VP 1961
Dr. Brian J. Caveney M.P.H., M.D., J.D., MPH Exec. VP, Pres of Diagnostics & Chief Medical Officer 1974
Mr. Mark S. Schroeder Exec. VP and Pres of Diagnostics Laboratory Operations & Global Supply Chain 1961
Dr. Paul R. Kirchgraber M.D. Exec. VP & CEO of Covance Drug Devel. 1962
Dr. Michelle Abelson Ph.D. Laboratory Director of Operations NA
Mr. Peter J. Wilkinson Sr. VP & Chief Accounting Officer 1972
Mr. Lance V. Berberian Exec. VP and Chief Information & Technology Officer 1963
Dr. Marcia T. Eisenberg Ph.D. Chief Scientific Officer & Sr. VP 1960
Chas Cook VP of Investor Relations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.88%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.16%

  • Financial Services

    +1.33%

  • Healthcare

    +1.50%

  • Industrials

    +2.97%

  • Real Estate

    +0.41%

  • Technology

    +1.27%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…